Health

Biotheus Announces the Closing of a New Round of Financing co-led by General Atlantic and IDG Capital

ZHUHAI, China, March 2, 2021 /PRNewswire/ -- Biotheus has announced the successful completion of a fourth round of financing, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a global leading investment firm. Other new investors include Kunlun Capital, CPE, an...

2021-03-03 11:37 1788

CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project

SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which ta...

2021-03-03 11:12 1775

VUNO presents its state-of-the-art AI medical imaging technology at ECR 2021

SEOUL, South Korea, March 2, 2021 /PRNewswire/ -- VUNO Inc., South Korean AI medical imaging company, will showcase its complete deep learning-based imaging offerings two years in a row in its virtual booth at the 2021 European Congress of Radiology (ECR), one of the biggest annual events, featur...

2021-03-02 23:00 2042

CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody

SUZHOU, China, March 2, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner QureBio Ltd ("QureBio") has announced its innovative drug Q-1802 received United States Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application. This applic...

2021-03-02 13:43 1863

China Biologic Announces Shareholders' Approval of Merger Agreement

BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company...

2021-03-01 21:00 10626

Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a$50 million series A financing, to accelerate its innovative pipeline developme...

2021-03-01 19:50 5136

CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers

SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 (CLDN18.2) targeted CAR-T product candidate ...

2021-03-01 19:00 4076

Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index

SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-03-01 08:00 6195

LISCure Biosciences Successfully Raises $21 million in Series B Funding

SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ -- On February 25th, 2021, LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, announced that it has successfully completed $21 million of a Series B funding round. Participants include institutional...

2021-02-26 22:00 3653

Alterity to present at the 7th International Congress of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...

2021-02-26 20:45 6746

Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization

HANGZHOU, China, Feb. 26, 2021 /PRNewswire/ -- China National Medical Products Administration (NMPA) announced onFebruary 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™). CanSino Biologics Inc. an...

2021-02-26 16:36 5538

Kyushu University Confirms HORIUCHI L-FUCOIDAN Inhibits Binding between ACE2 and Virus Spike Protein (Derived from COVID-19)

KURUME, Japan, Feb. 26, 2021 /PRNewswire/ -- FCC Horiuchi Co., Ltd. based in Kurume City,Fukuoka Prefecture, western Japan, has conducted an experiment in inhibiting binding between ACE2 and virus spike protein using HORIUCHI L-FUCOIDAN, manufactured by the company, in collaboration with a gradua...

2021-02-26 15:00 3587

ARANZ Medical's Silhouette® system becomes a national platform for wound telehealth assessments

CHRISTCHURCH, New Zealand, Feb. 25, 2021 /PRNewswire/ -- The US Department of Veteran's Affairs (VA) is establishingARANZ Medical's Silhouette solution as a VA national platform, enabling more VA Medical Centers to utilize Silhouette in their wound telehealth programs.

2021-02-26 09:39 2039

Biocytogen announces acquisition of a third Beacon Optofluidic system to support expanding Antibody Discovery Platform

BOSTON, Feb. 25, 2021 /PRNewswire/ -- Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen's antibody discove...

2021-02-25 23:45 1930

I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 piv...

2021-02-25 21:00 5164

Huami Corporation Announces Name Change to Zepp Health

BEIJING and CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ -- Huami Corp . today announced it is changing its name internationally to Zepp Health Corp. (NYSE: ZEPP) and the ticker symbol of its American depositary shares listed on the NYSE to "ZEPP" to better reflec...

2021-02-25 20:56 9586

111 to Announce Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results on March 18, 2021

SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2021-02-25 19:00 4832

Zhuyeqing The Epitome of Chinese Green Tea Ranks High in the "2021 Global Top 10 Luxury Tea Brands"

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- On February 24, 2021, Chinese brand Zhuyeqingranked high in the "2021 Global Top 10 Luxury Tea Brands", a global list that is compiled exclusively by one of the top three brand valuation organizations, World Brand Lab, to rank the best international high-en...

2021-02-25 16:21 5356

Turnaround on track at Comvita

TAURANGA, New Zealand, Feb. 24, 2021 /PRNewswire/ -- Headlines * Reported NPAT $3.5M vs. ($13M) in PCP * Reported EBITDA* $10.6M vs. ($8.8M) in PCP, an improvement of $19.4M * Reported revenue $98.9M, +5.5% vs. PCP * Double-digit top and bottom-line growth in focus growth markets * Net ...

2021-02-25 07:38 7108

Genome & Company and Debiopharm Join Forces To Create New Highly Specific Therapies for Cancer Patients

SEOUL, South Korea, Feb. 24, 2021 /PRNewswire/ -- Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading immuno-oncology firm, and Debiopharm, a Swiss-based biopharmaceutical company specializing in oncology and infectious diseases, today announced having entered into a research ...

2021-02-25 07:00 2781
1 ... 301302303304305306307 ... 313

Week's Top Stories